Genenta Science Spa (GNTA)

• $3.30

  $3.50

  $3.30
  

  0.0%

  Downside

  Day's Volatility :5.71%

  Upside

  5.71%

  
• $2.20

  $6.81

  $3.30
  

  33.33%

  Downside

  52 Weeks Volatility :67.69%

  Upside

  51.54%

  

Returns

What analysts predicted

Upside of 596.97%

• Bank Julius Baer & Co. Ltd, Zurich

  2.26%

• Algebris Investment Management (UK) LLP

  0.25%

cancer immunotherapy - our gene therapy science to treat cancer we develop a gene transfer strategy into autologous hematopoietic stem/progenitor cells (hspcs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages. an hiv-derived and genetically disabled viral vector - lentivirus - delivers the gene into the hspcs. interferon is a protein usually produced by the body in response to infections that also exhibits a powerful anti-tumor activity. however, the clinical use of interferon as a drug has been limited by its high toxicity. thanks to our innovative therapy, using a combination of transcriptional and microrna-mediated control, tumor-infiltrating monocytes/macrophages become capable to selectively express interferon limited to the tumor area, thus reducing its toxicity. based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, tie2-expressing monocytes (tems), are armed with a specific drug.